Medical testing provider Castle Bio raises annual revenue guidance
Overview
Castle Biosciences Q2 2025 revenue of $86.2 mln smashes analyst expectations
The medical testing provider raises full-year 2025 revenue guidance to $310-320 mln
Q2 test report volume increased 6% yr/yr
Outlook
Castle Biosciences raises 2025 revenue guidance to $310 mln-$320 mln
Previse acquisition and SciBase collaboration expected to support future growth
Result Drivers
CORE TEST GROWTH - DecisionDx-Melanoma and TissueCypher test volumes increased significantly, driving revenue performance
NON-COVERAGE IMPACT - Revenue affected by Novitas LCD non-coverage of DecisionDx-SCC and discontinuation of IDgenetix
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Beat | $86.19 mln | $71.40 mln (9 Analysts) |
Q2 Net Income | $4.52 mln | ||
Q2 Operating Expenses | $90.44 mln | ||
Q2 Operating Income | -$4.25 mln | ||
Q2 Pretax Profit | -$143,000 |
Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."
Wall Street's median 12-month price target for Castle Biosciences Inc is $36.00, about 59.3% above its August 1 closing price of $14.65
Press Release:
